Join the club for FREE to access the whole archive and other member benefits.

Sarconeos BIO101 in development for the treatment of Sarcopenia by Biophytis

SARA-INT Phase 2 study and SARA Phase 3 study milestones in developing sarconeos


Key points from article :

Development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes in patients suffering from age-related diseases, by Biophytis.

The major milestones in the development of Sarconeos (BIO101)- results of the SARA-INT Phase 2 study as well as the outline of SARA Phase 3 study, orally presented by Drs. Waly Dioh.

Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.

The duration of this study is estimated at 36 months from the inclusion of the first patient expected at the end of 2022.

Stanislas Veillet, CEO of Biophytis, states: "No drug is currently approved for sarcopenia in the world ... the first company to initiate a Phase 3 program."

The development of Sarconeos (BIO101) for the treatment of sarcopenia held at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders).

Mentioned in this article:

Click on resource name for more details.


Company focused on development of therapeutics that slow the degenerative processes associated with aging.

Stanislas Veillet

CEO and Founder of Biophytis

Waly Dioh

Chief Clinical Operations Officer of Biophytis

Topics mentioned on this page: